The NemetzGroup Announces Promotion of Marnie Hoolahan to President

New appointment will prepare the organization for the next phase of growth

Hoolahan will continue The NemetzGroup’s 20-year history of helping biopharma companies successfully take their therapies from development to market – and the patients who need them 

(December 5, 2023) Newton, MA – The NemetzGroup LLC today announced the promotion of Marnie Hoolahan to the role of president. This newly created position will be pivotal in shaping the company’s strategic direction and driving growth in the biopharma commercialization sector.

Since joining The NemetzGroup in 2012 as a consultant, Hoolahan has consistently demonstrated excellence across all domains of biopharma commercialization, assuming increased leadership responsibilities for complex client engagements, business development strategy, team management, and growth initiatives.

“Without question, Marnie’s passion for our clients and commitment to the business have benefited all who have had the pleasure of working with her,” said Susan Nemetz, founder and CEO of The NemetzGroup. “Her contributions have been integral to our team’s exceptional reputation in the biopharma industry.”

As president of The NemetzGroup, Hoolahan will assume additional responsibility for the firm’s strategic vision, financial growth, partnerships, and business operations. In this role, she will remain focused on elevating the commercialization efforts of biopharma clients while serving as a leader for others in the industry as the process of bringing medicines to market evolves and becomes increasingly important for a company’s long-term success.

“I am thrilled to assume this role at such an important time in our industry,” said Marnie Hoolahan, president of The NemetzGroup. “Over the past few years, we have witnessed changes that impact the viability of emerging and established biopharma companies, often determining whether patients receive life-saving medicines in development. For many companies, the right strategic advice at the right time can be a game changer in whether they make it to market. I am proud of the experienced team at The NemetzGroup and how we connect the dots for leaders. Working with our team can make all the difference in a company’s success.”

Prior to joining The NemetzGroup, Hoolahan held various leadership roles at Genzyme Corporation, GelTex, and Bristol-Myers Squibb. She is a member of the Life Science Cares Board of Advisors and Healthcare Businesswomen’s Association (HBA), serves as a mentor at the Wyss Institute, and is a supporter of the Termeer Foundation. She holds a Bachelor of Science in marketing and an MBA in entrepreneurial business and finance from Babson College.

Hoolahan will continue to report to Sue Nemetz, founder and CEO of both The NemetzGroup, a life science and strategy advisory firm, and Corval®, which offers an innovative cloud-based planning platform that enables biopharma teams to quickly create tailored, pre-populated, multiyear plans and budgets to navigate the path to market.

Nemetz continued, “This marks an exciting chapter in The NemetzGroup’s 20-year history. Marnie’s unparalleled expertise and experience will contribute to elevating commercialization strategy and planning in the biopharma industry, guiding future leaders, and improving efficiency to reduce obstacles along the path from development to market.”

About The NemetzGroup LLC:

The NemetzGroup is a life science and strategy advisory firm with deep expertise supporting emerging biopharma commercialization. The company collaborates with biopharma company leaders to develop strategies to navigate the commercialization continuum. The seasoned team of industry-trained professionals brings decades of experience working in the biotech and pharmaceutical industries to provide cross-functional counsel to clients at all stages of growth.

For more information, visit:

Media contact:

Kristin Faulder (on behalf of The NemetzGroup) (586) 419.4652